Proteomics International Laboratories’ 66 per cent-owned subsidiary OxiDx has picked up an Australian patent for its finger-prick technology to measure and monitor levels of oxidative muscle stress, which is linked to more than 70 diseases and the lion’s share of sports-related injuries.
The new copyright locks in the company’s intellectual property until 2039 and bolsters Proteomics’ global patent wallet, which already covers Europe, Japan and the United States. OxiDx has further filings pending in key Asian markets, including China, India and Singapore.
